However, this mode of regulation appears context-dependent: while NFE2L2 upregulates SLC40A1 expression in primary human macrophages treated with the GPX4 inhibitor RAS-selective lethal 3 (RSL3) (128), NFE2L2 downregulates SLC40A1 expression in ovarian cancer cells—this could constitute a rare example of direct repression by NFE2L2 (130). Here, SLC40A1 is linked to ovarian carcinoma.